Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

被引：3
|
作者：
Xin, Yan
Shao, Lixin
Deng, Wei
Niforos, Demi
Kowalski, Mark
Bavisotto, Linda M.
Kawashima, Jun
Jun, Susie
Collins, Helen
Ramanathan, Srinivasan
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1590.1590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1590
引用
收藏
页数：2
相关论文
共 38 条
  • [1] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [2] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Pardanani, A.
    Laborde, R. R.
    Lasho, T. L.
    Finke, C.
    Begna, K.
    Al-Kali, A.
    Hogan, W. J.
    Litzow, M. R.
    Leontovich, A.
    Kowalski, M.
    Tefferi, A.
    LEUKEMIA, 2013, 27 (06) : 1322 - 1327
  • [3] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    R R Laborde
    T L Lasho
    C Finke
    K Begna
    A Al-Kali
    W J Hogan
    M R Litzow
    A Leontovich
    M Kowalski
    A Tefferi
    Leukemia, 2013, 27 : 1322 - 1327
  • [4] Discovery of CYT387: A potent and selective dual inhibitor of JAK1 and JAK2
    Burns, Christopher J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [5] An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Litzow, Mark R.
    Hogan, William J.
    Begna, Kebede
    Smith, Gregg
    Bavisotto, Linda M.
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2011, 118 (21) : 1645 - 1645
  • [6] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
    Price, S.
    George, T.
    Pinilla-Ibarz, J.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
  • [7] Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis
    Pardanani, A. D.
    Caramazza, D.
    George, G.
    Lasho, T. L.
    Hogan, W. J.
    Litzow, M. R.
    Begna, K.
    Hanson, C. A.
    McClure, R. F.
    Bavisotto, L. M.
    Smith, G.
    Kowalski, M.
    Sirhan, S.
    Roberts, A. W.
    Gupta, V.
    Gotlib, J.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
    A Pardanani
    J Gotlib
    A W Roberts
    M Wadleigh
    S Sirhan
    J Kawashima
    J A Maltzman
    L Shao
    V Gupta
    A Tefferi
    Leukemia, 2018, 32 : 1034 - 1037
  • [9] Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
    Pardanani, A.
    Gotlib, J.
    Roberts, A. W.
    Wadleigh, M.
    Sirhan, S.
    Kawashima, J.
    Maltzman, J. A.
    Shao, L.
    Gupta, V.
    Tefferi, A.
    LEUKEMIA, 2018, 32 (04) : 1034 - 1037
  • [10] CYT387, a Novel Jak1/Jak2 Inhibitor, Prevents Progression of Pulmonary Arterial Hypertension in the Rat Monocrotaline Model
    Zisman, Lawrence S.
    Jain, Ritu
    Chin-Dusting, Jaye
    Andrews, Karen
    Court, Naomi
    Fantino, Emmanuelle
    Farrugia, Michelle
    Burns, Christopher J.
    CIRCULATION, 2010, 122 (21)
1234